Keros Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KROS research report →
About the company
Keros Therapeutics, Inc. , a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis.
- CEO
- Jasbir S. Seehra
- IPO
- 2020
- Employees
- 163
- HQ
- Lexington, MA, US
Price Chart
- Market Cap
- $360.30M
- P/E
- -4.61
- P/S
- 10.86
- P/B
- 1.47
- EV/EBITDA
- -1.07
- Div Yield
- 0.00%
- Gross Margin
- 96.48%
- Op Margin
- -332.55%
- Net Margin
- -256.60%
- ROE
- -17.04%
- ROIC
- -34.46%
- Revenue
- $244.06M · 6774.96%
- Net Income
- $87.01M · 146.44%
- EPS
- $2.34 · 146.80%
- Op Income
- $70.62M
- FCF YoY
- 165.08%
- 52W High
- $22.55
- 52W Low
- $9.69
- 50D MA
- $10.96
- 200D MA
- $14.76
- Beta
- 0.97
- Avg Volume
- 322.36K
Get TickerSpark's AI analysis on KROS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 15, 26 | BIENAIME JEAN JACQUES | buy | 1,000 |
| Jun 11, 26 | Newton Charles W. | sell | 550 |
| Jun 4, 26 | Farzan Nima | sell | 2,625 |
| Jun 4, 26 | Knowles Julius | sell | 2,625 |
| Jun 3, 26 | Seth Alpna | other | 7,142 |
| Jun 3, 26 | Seth Alpna | other | 7,433 |
| Jun 4, 26 | Seth Alpna | sell | 2,625 |
| Jun 3, 26 | GRAY MARY ANN | other | 7,142 |
| Jun 3, 26 | GRAY MARY ANN | other | 7,433 |
| Jun 3, 26 | Farzan Nima | other | 7,142 |
Our KROS coverage
Recent articles, reports, and earnings notes.
No research on KROS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KROS report →Similar companies
Peers in the same neighborhood.